CN101371844B - Sticking tablet for curing mouth ulcer using mometasone furoate as active component - Google Patents
Sticking tablet for curing mouth ulcer using mometasone furoate as active component Download PDFInfo
- Publication number
- CN101371844B CN101371844B CN2007100592593A CN200710059259A CN101371844B CN 101371844 B CN101371844 B CN 101371844B CN 2007100592593 A CN2007100592593 A CN 2007100592593A CN 200710059259 A CN200710059259 A CN 200710059259A CN 101371844 B CN101371844 B CN 101371844B
- Authority
- CN
- China
- Prior art keywords
- sticking tablet
- tablet
- plasticizer
- protective layer
- active component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000007117 Oral Ulcer Diseases 0.000 title claims description 20
- 206010028034 Mouth ulceration Diseases 0.000 title claims description 6
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 title description 5
- 229960002744 mometasone furoate Drugs 0.000 title description 2
- 239000004014 plasticizer Substances 0.000 claims abstract description 50
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000011241 protective layer Substances 0.000 claims abstract description 33
- 239000000945 filler Substances 0.000 claims abstract description 14
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 12
- 239000000314 lubricant Substances 0.000 claims abstract description 9
- 241000282414 Homo sapiens Species 0.000 claims abstract description 8
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 7
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 7
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 30
- 150000002148 esters Chemical class 0.000 claims description 28
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 25
- 239000010410 layer Substances 0.000 claims description 23
- 238000000576 coating method Methods 0.000 claims description 18
- 239000004375 Dextrin Substances 0.000 claims description 16
- 229920001353 Dextrin Polymers 0.000 claims description 16
- 235000019425 dextrin Nutrition 0.000 claims description 16
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 claims description 15
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims description 15
- 239000011248 coating agent Substances 0.000 claims description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 14
- -1 hydroxypropyl Chemical group 0.000 claims description 13
- 239000004925 Acrylic resin Substances 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 12
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 10
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 10
- 229960001631 carbomer Drugs 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 10
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 10
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 10
- 239000004593 Epoxy Substances 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 235000012424 soybean oil Nutrition 0.000 claims description 8
- 239000003549 soybean oil Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- PESZCXUNMKAYME-UHFFFAOYSA-N Citroflex A-4 Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)C(C(C)=O)C(=O)OCCCC PESZCXUNMKAYME-UHFFFAOYSA-N 0.000 claims description 5
- 235000005979 Citrus limon Nutrition 0.000 claims description 5
- 244000131522 Citrus pyriformis Species 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 239000002356 single layer Substances 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- WUPLWFRHWSPKJA-UHFFFAOYSA-N 2-hydroxy-4-oxoheptane-1,2,3-tricarboxylic acid Chemical compound CCCC(=O)C(C(O)=O)C(O)(C(O)=O)CC(O)=O WUPLWFRHWSPKJA-UHFFFAOYSA-N 0.000 claims description 4
- 235000019890 Amylum Nutrition 0.000 claims description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000003086 colorant Substances 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 210000000214 mouth Anatomy 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 238000005457 optimization Methods 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 abstract description 16
- 231100000397 ulcer Toxicity 0.000 abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 8
- 241001465754 Metazoa Species 0.000 abstract description 5
- 239000011347 resin Substances 0.000 abstract description 2
- 229920005989 resin Polymers 0.000 abstract description 2
- 239000012790 adhesive layer Substances 0.000 abstract 2
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 239000004584 polyacrylic acid Substances 0.000 abstract 1
- 239000011253 protective coating Substances 0.000 abstract 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 22
- 239000003814 drug Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 12
- 210000002200 mouth mucosa Anatomy 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 11
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 9
- 229960003657 dexamethasone acetate Drugs 0.000 description 9
- 230000000306 recurrent effect Effects 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000001035 drying Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000446313 Lamella Species 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000004408 titanium dioxide Substances 0.000 description 6
- 239000004804 Butyryltrihexylcitrate Substances 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003862 glucocorticoid Substances 0.000 description 5
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 5
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 5
- 239000011505 plaster Substances 0.000 description 5
- GWVUTNGDMGTPFE-UHFFFAOYSA-N trihexyl 2-butanoyloxypropane-1,2,3-tricarboxylate Chemical compound CCCCCCOC(=O)CC(C(=O)OCCCCCC)(OC(=O)CCC)CC(=O)OCCCCCC GWVUTNGDMGTPFE-UHFFFAOYSA-N 0.000 description 5
- 206010003694 Atrophy Diseases 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010020565 Hyperaemia Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- NXQMCAOPTPLPRL-UHFFFAOYSA-N 2-(2-benzoyloxyethoxy)ethyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCCOCCOC(=O)C1=CC=CC=C1 NXQMCAOPTPLPRL-UHFFFAOYSA-N 0.000 description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010040799 Skin atrophy Diseases 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 244000118681 Iresine herbstii Species 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229920000305 Nylon 6,10 Polymers 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 206010050172 Oral mucosa atrophy Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 229940053670 asmanex Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- BJAJDJDODCWPNS-UHFFFAOYSA-N dotp Chemical compound O=C1N2CCOC2=NC2=C1SC=C2 BJAJDJDODCWPNS-UHFFFAOYSA-N 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 210000004995 male reproductive system Anatomy 0.000 description 1
- 229960001293 methylprednisolone acetate Drugs 0.000 description 1
- PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940003691 nasonex Drugs 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940098458 powder spray Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002494 tetracaine hydrochloride Drugs 0.000 description 1
- CTJJGIVJOBVMEO-UHFFFAOYSA-N tetraoctyl benzene-1,2,4,5-tetracarboxylate Chemical compound CCCCCCCCOC(=O)C1=CC(C(=O)OCCCCCCCC)=C(C(=O)OCCCCCCCC)C=C1C(=O)OCCCCCCCC CTJJGIVJOBVMEO-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- AMMPRZCMKXDUNE-UHFFFAOYSA-N trihexyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CCCCCCOC(=O)CC(O)(C(=O)OCCCCCC)CC(=O)OCCCCCC AMMPRZCMKXDUNE-UHFFFAOYSA-N 0.000 description 1
- 125000005590 trimellitic acid group Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Abstract
The invention relates to a sticking tablet used for treating human or animal dental ulcer; the oral sticking tablet consists of an adhesive layer containing active components and a water insoluble protective layer; the inactive component containing in the adhesive layer consists of a filling agent, an adhesive sustained-released agent and a lubricant that are applicable to tablet, and the water insoluble protective layer consists of polyacrylic acid resin and/or ethyl cellulose which can be used as protective coatings and a plasticizer, and the active component is momestasone furoate.
Description
Technical field:
The present invention relates to the pharmaceutical composition and the application thereof of a kind of people of being used for the treatment of or mammal oral ulcer, relate in particular to a kind of oral cavity sticking tablet
Background technology:
Oral ulcer also is recurrent aphtha, is commonly called as aphtha, is a kind of common oral mucosa membrane disease.Recurrent oral ulceration refers to that specially a class is agnogenio, repeatedly outbreak but self limiting, isolated that produce, circular or oval-shaped ulcer are arranged.Be recurrent aphtha (aphtha is the meaning of Greek " scorching hot and ulcer ") or recurrent aphtha etc. again.Size, the depth and number difference according to the ulcer performance can be divided into three types again clinically: the light-duty oral ulcer of recurrent, recurrent stomatitis ulcer and mikulicz's ulcer.
Recurrent oral ulceration is one of modal disease in the diseases of oral mucosa, among people's all one's life, oral ulcer does not take place almost, just has the people to take place once in a while, has the people frequently to show effect; And about people of about 20% suffers from oral ulcer in various degree, and child, between twenty and fifty people and old people can be taken place, and it is fallen ill and does not have obvious relation season.Oral ulcer can betide any position of oral mucosa, and pinhead-sized dots in red appears in pathological changes initial stage mucous hyperemia, rubescent, edema, and the scorching hot discomfort of local sense has violent spontaneous pain; Stimulation such as hot and cold, sour, sweet all makes pain increase the weight of, and can show effect repeatedly.Though oral ulcer be oral disease, can spontaneous recovery because morbidity is frequent, the state of an illness increases the weight of gradually, brings and have a strong impact on for people's work, life.Recurrent oral ulceration cause of disease complexity is still not really clear and definite so far.Modern medicine is then thought: the variation of viral infection, bacterial infection, digestive system disease and dysfunction, hormonal change, spiritual neural factor, inherited genetic factors, immunologic function, and lack trace element zinc, ferrum, folic acid, vitamin B2, B6, B12 etc. in other factors such as the human body and can cause oral ulcer.
The present external used medicine of treatment oral ulcer, it is a variety of to comprise that Chinese medicine and western medicine has, the Chinese medicine class have with Borneolum Syntheticum, Indigo Naturalis, etc. be XILEI SAN, BINGPENG SAN, the pearl Huang of the main component infantile malnutrition powder such as loose that disappears, but this dosage form inconvenience when using is scattered and disappeared very soon behind the coating with saliva.Western medicine has gargarism, ointment, reaches the membrane of some medicines etc., main active component is the glucocorticoid that has based on dexamethasone, dexamethasone acetate, based on the antibiotic of metronidazole etc., based on the vitamin medicaments of vitamin B group, with lidocaine hydrochloride, tetracaine hydrochloride local anesthetic of representative etc.Wherein, most widely used with the Therapeutic Method of topical application glucocorticoid again.Disclose a kind of dexamethasone acetate plaster and preparation method thereof (i.e. " meaning can be pasted ", Shenzhen Mrs's Pharmaceutical is produced) as Chinese patent CN00132507.3, formed by a kind of adhered layer and a kind of fluid-tight protective layer of pastille.Dexamethasone acetate can play antiphlogistic effect, can promote ulcer surface to shrink, and quickens ulcer healing, yet because glucocorticoid has side effect, even topical application also is easy to generate systemic side effects when life-time service, i.e. the inhibition of hypothalamus-hypophysis-adrenal gland (HPA) axle.And used the plasticizer of harmful dioctyl phthalate as protective layer according to the described stickup tablet of this patent; each sticking tablet contains dioctyl phthalate up to 0.8mg; though this phthalic ester plasticizer acute toxicity is very little; yet; studies show that phthalic ester plasticizer exists very big chronic toxicity to human health; even zooscopy result both domestic and external shows the low dosage phthalic ester plasticizer, also can be to the nerve of animal, reproductive system especially male reproductive system toxigenicity.And from January 16th, 2007, European Union also implemented in EU countries about the instruction (2005/84/EC number instruction) of restriction toy and child care products phthalate (ester) content.According to this instruction, for toy and child care products, the content of phthalate (ester) all must not surpass 0.1%, and the potential hazard of the plasticizer of phthalate to the health existence is described thus from the side.Yet, open that upright superfine (plasticizer is preferred in the osmosis type acrylic resin coated slow release film, Acta Pharmaceutica Sinica, 2001,36 (12): 937-941) reported because the water-insoluble physical property of plasticizer of phthalate ideal plasticizer when being considered in the prior art prepare the waterproof coating.
At present the nontoxic plasticizer of generally acknowledging mainly contains just own ester etc. of citric acid ester plasticizer, epoxy soybean oil, trimellitic acid esters plasticizer, tetraoctyl 1,2,4,5-benzenetetra-carboxylate, diethylene glycol dibenzoate, DOTP, decanedioic acid two, wherein is most widely used with citric acid ester plasticizer again.And above-mentioned several plasticizer is mainly used in the purposes such as packing of food and medicine in the prior art, and does not use it for the report of plasticizer in the medicine coating.
Momestasone furoate (CAS:83919-23-7, Mometasone Furoate) is a kind of new external, the nonfluorinated class of the development and production of U.S. Schering Plough company, but contain " potent " glucocorticoid hormone preparation of halogen, at first went on the market in the U.S. in 1987.It has the chlorine atom on 9 and 21 of corticosteroid hormone structure, on 17 (2 ') position a furoate (also can be described as heterocycle) is arranged.Its chemical structural formula is: two chloro-11 β of 9 α-21-, 17 α-two hydroxy-16 alpha--methyl-pregnane-1,4-diene-3,20-diketone-17 (2 ') furoate.Be widely used in airway disorders such as treatment dermatosis, asthma, allergic rhinitis, main dosage form has 0.1% momestasone furoate emulsifiable paste (trade name " Eloson ", Schering Plough production) and 0.05% and 0.1% nasal spray (trade name " nasonex, Schering Plough production).And momestasone furoate powder spray (trade name " Asmanex ", Schering Plough production).Yu Ruiyao (momestasone furoate pharmacological characteristics and treatment dermatosis clinical efficacy, 1999 the 8th the 8th phases of volume of Chinese Journal of New Drugs) reported that the effect celestone-V of momestasone furoate is strong 4～6 times, patient or healthy volunteer's in vivo test have been shown less inhibition hpa axis.
Summary of the invention:
The invention provides a kind of is the stickup tablet of the nontoxic plasticizer of the use of active component with the momestasone furoate.
Every active component that contains of stickup tablet of the present invention is a momestasone furoate.The amount that every sticking tablet preferably contains active component is counted 0.01mg to 0.5mg with momestasone furoate, preferred 0.1mg to 0.2mg.For avoiding the side effect of glucocorticoid, the accumulated dose of the active component that use every day is no more than 2mg.
When stickup tablet of the present invention was used for the treatment of oral ulcer, used 1～3 preferred every day, uses 1～3 at every turn.
This tablet is made of adhesion layer that contains active component and water-fast protective layer, and the non-active ingredient that adhesion layer contained is by tablet filler commonly used, as amylum pregelatinisatum, lactose, sucrose,, in the mannitol, dextrin one or more, preferred dextrin; And the adhesion slow releasing agent includes but are not limited in carbomer (crosslinked polypropylene acid resin), polyvinylpyrrolidone (PVP), hydroxypropyl emthylcellulose (HPC), polyvinyl alcohol (PVA), sodium carboxymethyl cellulose (CMC-Na), hydroxypropyl cellulose (HPC), the hydroxypropyl emthylcellulose (HPMC) one or more, preferred carbomer.Can also contain lubricant for example but be not limited only to magnesium stearate, micropowder silica gel, Pulvis Talci, preferred magnesium stearate.
Adhesion layer described in every dose of sticking tablet can contain filler 10mg to 80mg, preferred 20mg to 50mg, and the consumption that adheres to slow releasing agent is 20% to 40% of a filler weight (dry weight), preferred 25% to 35%.Lubricant quantity is 0.05%～1% of an adhesion layer weight (dry weight).The weight of water-fast protective layer (dry weight) is 10%～20% of adhesion layer weight.
Water-fast protective layer in the described sticking tablet by can be as the protection polyacrylic resin of coating and/or ethyl cellulose, plasticizer, and optionally, pharmaceutically useful coloring agent and/or the white color ingot that can better differentiate the different layer of sticking tablet when order is used constitute.Described polyacrylic resin, (commodity are by name to comprise methacrylic acid and methyl methacrylate (1:1) copolymer (2005 editions described polyacrylic resin II of Chinese Pharmacopoeia) or methacrylic acid and ethyl acrylate (1:1) copolymer
L100-55 and
L30D-55 originates from German Degussa company), preferred
L100-55 or
L30D-55.When selecting ethyl cellulose for use, also need use plasticizer.Described white color ingot is preferred but be not limited only to titanium dioxide, described coloring agent be can be medicinal pigment, preferably but be not limited only in yellow ferric oxide, Brown Ferric Oxide, the red ferric oxide one or more.
Described plasticizer can be selected from but be not limited only to epoxy soybean oil, in the citric acid ester plasticizer one or more, described citric acid ester plasticizer can be enumerated but be not limited to citric acid tri-n-hexyl ester (THC), the just own ester of acetyl tributyl citrate three (ATHC), trioctyl lemon acid (TOC), acetyl tributyl citrate three monooctyl esters (ATOC), tributyl citrate (TBC), tributyl 2-acetylcitrate (ATBC), citric acid three own esters (THC), acetyl tributyl citrate three own esters (ATHC), butyryl citric acid three own esters (BTHC), plasticizer optimization citric acid tributyl and/or tributyl 2-acetylcitrate.Described plasticizer consumption is 5% to 30%, preferred 10%～25% of a protective layer weight (dry weight).
Technical scheme of the present invention can also be made only has the monolayer sticking tablet of adhesion layer as mentioned above.
Stickup tablet of the present invention (above-mentioned monolayer, double-deck sticking tablet) prepares by the following method: active component is dissolved; mix with filler after granulate, granulate; tabletting promptly gets the monolayer sticking tablet after add adhering to slow releasing agent and magnesium stearate mixing, and the solution spraying that will contain acrylic resin, plasticizer and pigment by Membrane jetter is made protective layer in the tablet surface and promptly got double-deck sticking tablet again.
The double-deck tablet of pasting of the present invention has overcome existing stickup tablet in the prior art uses the phthalate of potential hazard to the person the defective of plasticizer, has used the plasticizer nontoxic to human body instead.Show that by the contrast experiment compared with prior art effect is suitable for the protective action of employing nontoxic plasticizer protective layer, even better, has overcome the potential hazard of original phthalic ester plasticizer to human body.
Show by experimental example 2, momestasone furoate is the sticking tablet of active component, when drug effect improves, the side effect that causes atrophoderma also obviously reduces, can draw when acting on oral mucosa thus, the side effect that causes atrophy to oral mucosa also can greatly reduce, and the oral mucosa atrophy itself is exactly a kind of important clinical symptom performance of oral ulcer, except the therapeutical effect to ulcer surface, thereby its low atrophic that causes has special therapeutical effect for the treatment oral ulcer to the sticking tablet of employing momestasone furoate active component when the treatment oral ulcer.In addition, oral ulcer for recurrent, owing to need treat repeatedly at same position, thereby so to adopt low atrophic active component such as the momestasone furoate of causing be that the sticking tablet of active component can avoid the atrophy of oral mucosa to reach better therapeutic effect in the treatment oral ulcer preferably.
To product of the present invention by illumination (2500LUX), high temperature (40 ℃, 60 ℃, 80 ℃, high humidity (RH75%, 92.5%), each influence factor of 10 days test of air at room temperature, the study on the stability that accelerated test (40 ℃, RH75%) three months and room temperature kept sample 24 months, its medicated layer character, related substance, dissolubility, content etc. have no significant change.
Compositions effect of the present invention is to pass through mucosa absorption, employing is the sticking tablet of the present invention (as embodiment 1,3,5,7 made sticking tablets) of active component with the momestasone furoate, with the chicken gizzard capsule is biomembranous model, can observe principal agent compare by mucosa absorption and with the ordinary tablet of same dose active component, and the transmitance situation saw the following form in 5 hours as a result
Table 15 hour transmitance information slip
| Embodiment 1/ ordinary tablet | Embodiment 2/ ordinary tablet | Embodiment 3/ ordinary tablet | Embodiment 4/ ordinary tablet | Embodiment 5/ ordinary tablet | Embodiment 6/ ordinary tablet | Embodiment 7/ ordinary tablet | Embodiment 8/ ordinary tablet | |
| MP％ | 65/47 | 58/40 | 60/50 | 59/40 | 62/45 | 63/45 | 61/42 | 62/44 |
(the tinidazole oral film is to the therapeutical effect of experimental rat periodontitis and to the research of oral mucosa zest, Chinese clinical pharmacology and therapeutics, 2004Jan with reference to Wang Linhui etc. for product of the present invention; 9 (1)) disclosed mucomembranous irritant test method, observe the stimulation of this product to the oral mucosa of rat, the result shows: this product and excipient contrast level (blank sticking tablet), successive administration 7 days, 1 hour hour execution rat after the last administration, observe the rat oral mucosa, the result does not have obvious hyperemia and edema phenomenon, and histopathologic examination and matched group do not see that the mucosa morphosis is unusual.
Specific embodiment
Embodiment 1
Paste lamella
Momestasone furoate 0.1g
Carbomer 10g
Dextrin 30g
Magnesium stearate 0.03g
Protective layer
L100-55 4g
Titanium dioxide 1g
Yellow ferric oxide 1g
Tributyl 2-acetylcitrate (ATBC) 0.8g
Preparation technology:
With momestasone furoate 5ml anhydrous alcohol solution, the solution of above-mentioned active component was joined in the dextrin of 100 mesh sieves fully mixing after 30 mesh sieves are granulated, after 60 ℃ of oven dry, through 40 mesh sieve granulate, after adding the abundant mixing of carbopol, magnesium stearate of 100 mesh sieves, promptly get 1000 with diameter 6mm flat punch tabletting, every contains momestasone furoate 0.10mg.With recipe quantity
L100-55 dissolves with 95% alcohol 95 ml, adds ATBC, titanium dioxide, the yellow ferric oxide of recipe quantity, every heavily about 50mg.
Embodiment 2
The prescription of embodiment 1 changes active component into momestasone furoate 0.2g, and plasticizer changes other preparation technologies of tributyl citrate (TBC) into embodiment 1
Embodiment 3
Paste lamella
Momestasone furoate 0.5g
Carbomer 5g
Polyvinylpyrrolidone (PVP) 3g
Dextrin 30g
Magnesium stearate 0.05g
Protective layer
L100-55 4g
Titanium dioxide 0.5g
Citric acid three own ester (THC) 0.8g
Preparation technology:
With an amount of anhydrous alcohol solution of momestasone furoate, the solution of above-mentioned active component was joined in the dextrin of 100 mesh sieves fully mixing after 30 mesh sieves are granulated, after 60 ℃ of oven dry, through 40 mesh sieve granulate, after adding the abundant mixing of carbomer, PVP, magnesium stearate of 100 mesh sieves, promptly get 1000 with diameter 6mm flat punch tabletting, contain methylprednisolone 0.5mg with recipe quantity
L100-55 dissolves with 95% alcohol 95 ml, and the THC, the titanium dioxide that add recipe quantity grind evenly, evenly are sprayed at the tablet surface with Membrane jetter, form the protective layer of tablet after drying, every heavily about 50mg.
Embodiment 4
As the prescription of embodiment 3, change active component into momestasone furoate 0.3g, change plasticizer into acetyl tributyl citrate three own esters (ATHC).Other preparation technologies are with embodiment 3.
Embodiment 5
Paste lamella
Momestasone furoate 0.01g
Carbomer 5g
Hydroxypropyl cellulose (HPC) 3g
Dextrin 30g
Magnesium stearate 0.05g
Protective layer
Epoxy soybean oil 0.6g
Preparation technology:
With momestasone furoate with an amount of anhydrous alcohol solution after, joined in the dextrin of 100 mesh sieves fully mixing respectively after 30 mesh sieves are granulated, after 60 ℃ of oven dry, through 40 mesh sieve granulate, after adding the abundant mixing of carbomer, HPC, magnesium stearate of 100 mesh sieves, promptly get 1000 with diameter 6mm flat punch tabletting, contain methylprednisolone 1.0mg.With recipe quantity
30D-55 dissolves with 95% alcohol 95 ml, and the epoxy soybean oil grinding that adds recipe quantity is even, evenly is sprayed at the tablet surface with Membrane jetter, after drying, forms the protective layer of tablet.Every heavily about 50mg
Embodiment 6
Paste lamella
Momestasone furoate 0.03g
Polyvinylpyrrolidone (PVA) 5g
Hydroxypropyl emthylcellulose (HPMC) 5g
Amylum pregelatinisatum 30g
Magnesium stearate 0.05g
Protective layer
Trioctyl lemon acid (TOC) 1.5g
Behind an amount of anhydrous alcohol solution of furancarboxylic acid Mo Meisong, joined in the dextrin of 100 mesh sieves fully mixing respectively after 30 mesh sieves are granulated, after 60 ℃ of oven dry, through 40 mesh sieve granulate, after adding the abundant mixing of PVA, HPMC, magnesium stearate of 100 mesh sieves, get 1000 with diameter 6mm flat punch tabletting, every heavily about 50mg contains methylprednisolone acetate 0.7mg.With recipe quantity
30D-55 dissolves with 95% alcohol 95 ml, and the TOC that adds recipe quantity grinds evenly, evenly is sprayed at the tablet surface with Membrane jetter, after drying, forms the protective layer of tablet.
Embodiment 7
Paste lamella
Momestasone furoate 0.05g
Sodium carboxymethyl cellulose (CMC-Na) 5g
Hydroxypropyl cellulose (HPC) 7g
Dextrin 30g
Pulvis Talci 0.1g
Protective layer
Acetyl tributyl citrate three monooctyl esters (ATOC) 1.5g
Titanium dioxide 0.5g
With momestasone furoate with an amount of dissolve with ethanol after, joined in the dextrin of 100 mesh sieves fully mixing respectively after 30 mesh sieves are granulated, after 60 ℃ of oven dry, through 40 mesh sieve granulate, after adding the abundant mixing of CMC-Na, HPC, Pulvis Talci of 100 mesh sieves, get 1000 with diameter 6mm flat punch tabletting, every heavily about 50mg contains momestasone furoate 0.06mg.With recipe quantity
30D-55 dissolves with 95% alcohol 95 ml, and the ATOC that adds recipe quantity grinds evenly, evenly is sprayed at the tablet surface with Membrane jetter, after drying, forms the protective layer of tablet.
Embodiment 8
Paste lamella
Momestasone furoate 0.08g
Sodium carboxymethyl cellulose (CMC-Na) 5g
Hydroxypropyl emthylcellulose (HPMC) 7g
Dextrin 30g
Magnesium stearate 0.2g
Protective layer
Ethyl cellulose 4g
Butyryl citric acid three is ester (BTHC) 1.5g
With the momestasone furoate of recipe quantity with an amount of anhydrous alcohol solution after, joined in the dextrin of 100 mesh sieves fully mixing after 30 mesh sieves are granulated, after 60 ℃ of oven dry, through 40 mesh sieve granulate, after adding the abundant mixing of CMC-Na, HPMC, Pulvis Talci of 100 mesh sieves, get 1000 with diameter 6mm flat punch tabletting, every heavily about 50mg contains momestasone furoate 0.08mg.The ethyl cellulose of recipe quantity is dissolved with 95% alcohol 95 ml, and the BTHC that adds recipe quantity grinds evenly, evenly is sprayed at the tablet surface with Membrane jetter, after drying, forms the tablet protective layer.
Embodiment 9～16
Press prescription and the method preparation monolayer of embodiment 1～8 respectively and paste tablet.
The contrast of test comparative example 1 drug effect
Experimental drug: be mixed with sticking tablet according to embodiment 1～8
Laboratory animal: 44 of healthy Japan large ear rabbits, body weight 2.0～2.5kg, male and female are not limit.
Experimental technique:
1. modeling
With reference to Chen Ke, Ren Yuguang, Luo Yuning etc. (animal experiment study of Chinese document laser therapy oral ulcer, YAG. uses laser, and 1998,18 (3): 135～136) disclosed method grinds the hole that diameter is 3mm with the plastic centrifuge tube bottom.Be stained with 90% carbolic acid (moistening, do not overflow be degree) with cotton pellet and put aperture place in the pipe; Rabbit is used 3% Nembutal vein anesthetic, retract upperlip, expose buccal, oral cavity mucosa, centrifuge tube burnt 30 seconds perpendicular to oral mucosa, made local oral mucosa be pale asphyxia.Wound surface forms roun ulcer next day, the surface is congested, no pseudomembrane, and the border is more clear.Two ulcer surfaces about every rabbit is burnt.Respectively form ulcer hyperemia, the edema situation of face and carry out integration relatively.
2. experiment
Be divided into 11 groups at random after the modeling success, prepare dexamethasone acetate plaster according to Chinese patent 00132507.8 disclosed method and be the prior art matched group for 3 kinds, every dexamethasone acetate content is respectively 0.1mg, 0.3mg, 0.5mg is divided into existing 1,2,3.And the sticking tablet that makes of embodiment 1～8 to be divided into be 11 experimental grouies and positive controls, following table between the grouping situation
Table 2: grouping information slip
| Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 | Embodiment 6 | Embodiment 7 | Embodiment 8 | Existing 1 | Existing 2 | Existing 3 | Positive control |
| A1 | A2 | A3 | A4 | A5 | A6 | A7 | A8 | B1 | B2 | B3 | C |
Experimental technique:
2 each a slices of every group of administration every day are pasted other medicine of respective sets, and blank group is coated with normal saline.The ulcer area of each group of different time sees Table 3 in the treatment
Ulcer area (the mm of each group of different time in table 3 treatment
2))
| Group | Active component mg/ sheet | Before the treatment | Treat after 1 day | Treat after 2 days | Treat after 3 days |
| A1 | 0.1 | 45.81±1.08 | 39.21±1.21 | 33.69±1.14 | 26.52±0.98 |
| A2 | 0.2 | 46.30±1.50 | 37.87±1.01 | 32.01±0.92 | 24.45±1.01 |
| A3 | 0.5 | 45.63±1.14 | 35.01±1.03 | 27.49±0.91 | 20.98±0.87 |
| A4 | 0.3 | 46.51±0.99 | 36.49±0.79 | 29.29±1.12 | 22.74±0.93 |
| A5 | 0.01 | 45.31±1.05 | 43.14±1.21 | 38.63±0.99 | 35.18±0.92 |
| A6 | 0.03 | 45.27±1.11 | 42.18±0.79 | 36.91±1.12 | 32.87±1.03 |
| A7 | 0.05 | 46.35±0.89 | 41.10±1.09 | 35.18±0.87 | 30.89±0.96 |
| A8 | 0.08 | 46.06±1.16 | 39.78±0.78 | 34.12±0.97 | 28.14±0.94 |
| B1 | 0.1 | 45.53±1.33 | 43.22±0.99 | 38.14±1.05 | 33.67±0.69 |
| B2 | 0.3 | 46.01±1.14 | 40.91±1.14 | 35.14±0.84 | 28.03±0.92 |
| B3 | 0.5 | 46.29±0.86 | 39.88±1.16 | 33.75±1.33 | 27.04±0.95 |
| C | 45.57±0.93 | 47.02±1.05 | 45.98±0.97 | 44.14±0.76 |
From the experimental result of table 3, each experimental group is compared during with positive controls corresponding treatment natural law, and the ulcer area all has significance (P＜0.05).
And A1, A6, A8 group is formed contrast with B3, B1, B2 as prior art respectively, ulcer area during the corresponding treatment natural law does not have significance (P〉0.05), this explanation is under this drug effect embodiment condition, momestasone furoate only need be used lower dosage when reaching the same effect of dexamethasone acetate, and curative effect is better than dexamethasone acetate plaster far away under the Isodose.Test comparative example 2, local action causes atrophy effect contrast
Laboratory animal: 50 of white Cavia porcelluss childhood, body weight 300g ± 20g
Experiment medicine: A group medicine, (the 0.3mg/ sheet is by prior art manufacturing among the test comparative example 1 for dexamethasone acetate plaster.
B organizes medicine, and the sticking tablet that makes according to embodiment 1～8 is divided into B1～B8 group respectively.
Grouping and experiment: Cavia porcellus is divided into 5 groups at random, and A organizes (dexamethasone acetate plaster), and B1～B8 organizes (sticking tablet that embodiment 1～8 makes)
Just every guinea pig back left and right sides antimere selects the zone of 3cm * 3cm, shaves hair, and the experimental group sticking tablet is labelled to a side, and the blank sticking tablet of corresponding embodiment is used in the another side.Medication every day 2 times was pasted 5 hours at every turn.Continuous use, after medication the 5th day with every group of Cavia porcellus drug withdrawal, medication district, back and check plot skin are put to death and got respectively to Cavia porcellus, the ratio of measuring medication district skin thickness and check plot skin thickness is to determine the atrophoderma degree.The results are shown in Table 6
Compare with A group, (atrophy degree that causes of B1～B8) has significance (P＜0.05) to the B group, momestasone furoate is described thus when local action, and side effect is littler.The toleration of body is better.
The contrast of test comparative example 2 coatings barrier propterties
The effect key of enforcement of the present invention is the barrier propterty of coatings, have only barrier propterty good, fluid-tight coatings can better realize that just technique effect of the present invention promptly reduces dissolving and tablet the two-way adhesion between gums and oral mucosa of medicine to the offside of mucosa.
Equipment:; Teflon coils (Shanghai Chemical Plant's customization)), calibrator (0.001mm, Taizhou Jiangjiang Seiko measurer company), digestion instrument
Produce disclosed coating solution among coating solution in the embodiment of the invention 1～8 and the ZL00132507.8 embodiment respectively.Quantitatively move in the Teflon dish that is stamped upside down funnel,, choose thickness 350 ± 50 μ m and examine under a microscope the film of no indentation standby in (20 ± 1) ℃, 60% time drying of relative humidity (RH) 48 hours.
The coating membrane that disclosed coating solution is made among coating membrane that coating solution among the embodiment 1～8 is made and the ZL00132507.8 embodiment is divided into 1～8 group of embodiment and matched group, every group of 3 films, every 300mg is respectively in the digestion instrument of the phosphate buffered solution that fills pH6.8, at 37 ℃, stripping is 8 hours under the 100r/min, blot the film surface moisture with filter paper after precision weigh (ml), place drying to think highly of to constant weight film, precision is weighed (m2), surveys water absorption rate and plasticizer dissolution rate.
Water absorption rate %=(m1-m2)/m2 * 100%
Heavy plasticizer weight/(300mg * plasticizer loading) of plasticizer dissolution rate=buffer
Experimental result sees Table 4
Table 4: coating membrane water absorption rate and plasticizer dissolution rate meansigma methods table
| Water absorption rate % | Plasticizer dissolution rate % | |
| Embodiment 1 (ATBC) | 3.42 | 2.98 |
| Embodiment 2 (TBC) | 3.14 | 2.72 |
| Embodiment 3 (THC) | 2.83 | 2.15 |
| Embodiment 4 (ATHC) | 2.50 | 1.75 |
| Embodiment 5 (epoxy soybean oil) | 3.01 | 2.64 |
| Embodiment 6 (TOC) | 1.37 | 0.95 |
| Embodiment 7 (ATOC) | 1.40 | 0.97 |
| Embodiment 8 (BTHC) | 1.48 | 0.85 |
| Matched group (DOP) | 2.52 | 2.01 |
As can be seen from Table 4; respectively organize plasticizer among the embodiment and can both reach the certain protection effect; (water absorption rate＜7%; plasticizer dissolution rate＜5%); the water absorption rate of the coating membrane of gained is compared quite with matched group or is omited with the plasticizer dissolution rate when preferred TOC, ATOC, BTHC especially; illustrate that the various plasticizers that the present invention selects for use are the goal of the invention that citric acid ester plasticizer, epoxy soybean oil all can be realized the protective layer coating, make the sticking tablet that makes reach the effect of unidirectional administration.
Claims (10)
1. oral cavity sticking tablet that is used for the treatment of human mouth ulcer, constitute by adhesion layer that contains active component and water-fast protective layer, the non-active ingredient that adhesion layer contains is by the filler that is applicable to tablet, adhering to slow releasing agent and lubricant forms, described water-fast protective layer is by can be used as polyacrylic resin or the ethyl cellulose that protects coating, constitute with plasticizer, it is characterized in that, described active component is a momestasone furoate, every sticking tablet contains active component 0.01mg to 0.5mg, the filler 10mg to 80mg that adhesion layer described in every sticking tablet contains, comprise amylum pregelatinisatum, lactose, sucrose, mannitol, in the dextrin one or more, the consumption of described adhesion slow releasing agent is 20% to 40% of a filler dry weight, comprise carbomer, polyvinylpyrrolidone, hydroxypropyl emthylcellulose, polyvinyl alcohol, sodium carboxymethyl cellulose, in the hydroxypropyl cellulose one or more, described lubricant quantity is 0.05% to 1% of an adhesion layer dry weight, is magnesium stearate, microcrystalline Cellulose, in the Pulvis Talci one or more; The weight of described water-fast protective layer is 10% to 20% of adhesion layer weight; described polyacrylic resin is polyacrylic resin II and/or methacrylic acid and 1: 1 copolymer of ethyl acrylate; described plasticizer is one or more in epoxy soybean oil, citric acid three own esters, acetyl tributyl citrate three own esters, trioctyl lemon acid, acetyl tributyl citrate three monooctyl esters, tributyl citrate, tributyl 2-acetylcitrate, the butyryl citric acid three own esters, and described plasticizer consumption is 5% to 30% of a protective layer dry weight.
2. oral cavity sticking tablet that is used for the treatment of human mouth ulcer, constitute by adhesion layer that contains active component and water-fast protective layer, the non-active ingredient that adhesion layer contains is by the filler that is applicable to tablet, adhering to slow releasing agent and lubricant forms, described water-fast protective layer is by can be used as polyacrylic resin or the ethyl cellulose that protects coating, and plasticizer, and pharmaceutically useful coloring agent constitutes, it is characterized in that, described active component is a momestasone furoate, every sticking tablet contains active component 0.01mg to 0.5mg, the filler 10mg to 80mg that adhesion layer described in every sticking tablet contains, comprise amylum pregelatinisatum, lactose, sucrose, mannitol, in the dextrin one or more, the consumption of described adhesion slow releasing agent is 20% to 40% of a filler dry weight, comprise carbomer, polyvinylpyrrolidone, hydroxypropyl emthylcellulose, polyvinyl alcohol, sodium carboxymethyl cellulose, in the hydroxypropyl cellulose one or more, described lubricant quantity is 0.05% to 1% of an adhesion layer dry weight, is magnesium stearate, microcrystalline Cellulose, in the Pulvis Talci one or more; The weight of described water-fast protective layer is 10% to 20% of adhesion layer weight; described polyacrylic resin is polyacrylic resin II and/or methacrylic acid and 1: 1 copolymer of ethyl acrylate; described plasticizer is one or more in epoxy soybean oil, citric acid three own esters, acetyl tributyl citrate three own esters, trioctyl lemon acid, acetyl tributyl citrate three monooctyl esters, tributyl citrate, tributyl 2-acetylcitrate, the butyryl citric acid three own esters, and described plasticizer consumption is 5% to 30% of a protective layer dry weight.
3. sticking tablet as claimed in claim 1 or 2, the every preferred 0.1mg to 0.2mg of active component that sticking tablet contains.
4. sticking tablet as claimed in claim 1 or 2 is characterized in that in described plasticizer optimization citric acid three own esters, acetyl tributyl citrate three own esters, trioctyl lemon acid, acetyl tributyl citrate three monooctyl esters one or more.
5. sticking tablet as claimed in claim 1 or 2 is characterized in that the preferred dextrin of filler of described adhesion layer.
6. sticking tablet as claimed in claim 1 or 2 is characterized in that the preferred magnesium stearate of lubricant in the described adhesion layer.
7. sticking tablet as claimed in claim 1 or 2 is characterized in that the preferred carbomer of adhesion slow releasing agent in the described adhesion layer.
8. sticking tablet as claimed in claim 1 or 2 is characterized in that the consumption of the adhesion slow releasing agent in the described adhesion layer is preferably 25% to 35% of filler dry weight.
9. sticking tablet as claimed in claim 1 or 2 is characterized in that plasticizer dosage is preferably 10% to 25% of protective layer dry weight in the described protective layer.
10. sticking tablet as claimed in claim 2; can prepare by the following method: active component is dissolved; mix with filler after granulate, granulate; tabletting promptly gets the monolayer sticking tablet after add adhering to slow releasing agent and lubricant mixing, and the solution spraying that will contain polyacrylic resin, plasticizer and coloring agent by Membrane jetter is made protective layer in the tablet surface and promptly got double-deck sticking tablet again.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100592593A CN101371844B (en) | 2007-08-23 | 2007-08-23 | Sticking tablet for curing mouth ulcer using mometasone furoate as active component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100592593A CN101371844B (en) | 2007-08-23 | 2007-08-23 | Sticking tablet for curing mouth ulcer using mometasone furoate as active component |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101371844A CN101371844A (en) | 2009-02-25 |
| CN101371844B true CN101371844B (en) | 2011-06-15 |
Family
ID=40446343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100592593A Active CN101371844B (en) | 2007-08-23 | 2007-08-23 | Sticking tablet for curing mouth ulcer using mometasone furoate as active component |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101371844B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1389200A (en) * | 2000-11-24 | 2003-01-08 | 深圳太太药业股份有限公司 | Dexamethasone acetate plaster and its prepn. |
| CN1652781A (en) * | 2002-04-09 | 2005-08-10 | 弗拉梅技术公司 | Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin |
-
2007
- 2007-08-23 CN CN2007100592593A patent/CN101371844B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1389200A (en) * | 2000-11-24 | 2003-01-08 | 深圳太太药业股份有限公司 | Dexamethasone acetate plaster and its prepn. |
| CN1652781A (en) * | 2002-04-09 | 2005-08-10 | 弗拉梅技术公司 | Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin |
Non-Patent Citations (2)
| Title |
|---|
| F Teixeira.Treatment of recurrent oral ulcers with mometasone furoate lotion.《 The Fellowship of Postgraduate Medicine》.1999,第75卷第574页中栏第47行至第58行，右栏第2行至第29行. * |
| 鲁凤兰.无毒增塑剂的生产与应用.《精细石油化工进展》.2006,第7卷(第9期),第40页第1.2栏,第41页第2.1.2栏和第44页第2.6栏. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101371844A (en) | 2009-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101371845B (en) | Medicament composition for curing mouth ulcer | |
| US11583519B2 (en) | Nasal compositions and method of use thereof | |
| SA01210740A (en) | Extended release oral dosage composition. | |
| JP2017528457A5 (en) | ||
| AU657573B2 (en) | Oral preparation for release in lower digestive tracts | |
| KR100794264B1 (en) | Multilayer buccal mucoadhesive dosage forms | |
| CN101703513A (en) | Compound sustained-release preparation of aspirin and clopidogrel or pharmaceutically acceptable salt thereof | |
| WO2021129735A1 (en) | Solid preparation, and preparation method therefor and use thereof | |
| WO2007144083A2 (en) | Ache-nmda combination wafer | |
| CN101278948B (en) | Biological medical membrane and method of preparing the same | |
| CN101371824B (en) | Oral cavity pasting tablets using Methylprednisolone and derivatives thereof as active components | |
| CN101095800A (en) | Development of paster for treating mouth ulcer | |
| CN104739809B (en) | Film of water-insoluble drug of high drug load and preparation method thereof can be provided | |
| EP2029097A2 (en) | Combination antidepressants wafer | |
| CN101108172B (en) | Oral sticking tablet and method of preparing the same | |
| CN107582536A (en) | A kind of CBS oral cavity adherent emplastrum and preparation method thereof | |
| CN101371844B (en) | Sticking tablet for curing mouth ulcer using mometasone furoate as active component | |
| Jana et al. | Current drug delivery strategies for buccal cavity ailments using mouth dissolving wafer technology: a comprehensive review on the present state of the art | |
| CN104434829B (en) | A kind of Essential Oil of Acorus tatarinowii oral quick disintegrating tablet and preparation method thereof | |
| CN101444567A (en) | Double-layer traditional Chinese medicine patch for treating oral ulcer and preparation method thereof | |
| CN1954843B (en) | Traditional Chinese medicine plaster for treating tunica mucosa oris ulcer and its preparation method | |
| CN101371825B (en) | Oral sticking tablets using fluticasone propionate as active component | |
| CN103494827B (en) | Compound buccal adhesive tablet containing triamcinolone acetonide and preparation method thereof | |
| CN102429893A (en) | Anti-inflammation and anti-allergy canker sore treating medicament and preparation method thereof | |
| US20110091536A1 (en) | Compositions comprising euphorbia prostrata and process of preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Sun Liang Document name: Notification of Passing Examination on Formalities |
|
| DD01 | Delivery of document by public notice | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 300161 Hedong Road, Hedong District, Tianjin, No. 91 Patentee after: Tianjin Pharmaceutical Research Institute Co.,Ltd. Address before: 300161 Hedong Road, Hedong District, Tianjin, No. 91 Patentee before: TIANJIN PHARMACEUTICALS Group Corp. |
|
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 300457 Tianjin Binhai New Area Tianjin Development Zone West District Xinye Jiujie north, Xinhuan West Road East Patentee after: Tianjin Pharmaceutical Research Institute Co.,Ltd. Address before: 300161 Hedong Road, Hedong District, Tianjin, No. 91 Patentee before: Tianjin Pharmaceutical Research Institute Co.,Ltd. |
|
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 300457 North Xinye 9th Street and East Xinhuan West Road, West District, Binhai New Area Development Zone, Tianjin Patentee after: Tianjin Pharmaceutical Research Institute Co.,Ltd. Address before: 300457 Tianjin Binhai New Area Tianjin Development Zone West District Xinye Jiujie north, Xinhuan West Road East Patentee before: Tianjin Pharmaceutical Research Institute Co.,Ltd. |